JP5101288B2 - アプタマー調節される核酸及びその利用 - Google Patents

アプタマー調節される核酸及びその利用 Download PDF

Info

Publication number
JP5101288B2
JP5101288B2 JP2007534921A JP2007534921A JP5101288B2 JP 5101288 B2 JP5101288 B2 JP 5101288B2 JP 2007534921 A JP2007534921 A JP 2007534921A JP 2007534921 A JP2007534921 A JP 2007534921A JP 5101288 B2 JP5101288 B2 JP 5101288B2
Authority
JP
Japan
Prior art keywords
nucleic acid
aptamer
ligand
cell
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007534921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008515405A (ja
JP2008515405A5 (enExample
Inventor
ディー．スモルク クリスティナ
エス．ベイヤー トラヴィス
Original Assignee
カリフォルニア インスティテュート オブ テクノロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリフォルニア インスティテュート オブ テクノロジー filed Critical カリフォルニア インスティテュート オブ テクノロジー
Publication of JP2008515405A publication Critical patent/JP2008515405A/ja
Publication of JP2008515405A5 publication Critical patent/JP2008515405A5/ja
Application granted granted Critical
Publication of JP5101288B2 publication Critical patent/JP5101288B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2007534921A 2004-10-05 2005-10-05 アプタマー調節される核酸及びその利用 Expired - Fee Related JP5101288B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61597704P 2004-10-05 2004-10-05
US60/615,977 2004-10-05
US64165805P 2005-01-06 2005-01-06
US60/641,658 2005-01-06
PCT/US2005/036161 WO2006042112A2 (en) 2004-10-05 2005-10-05 Aptamer regulated nucleic acids and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012178625A Division JP5795563B2 (ja) 2004-10-05 2012-08-10 アプタマー調節される核酸及びその利用

Publications (3)

Publication Number Publication Date
JP2008515405A JP2008515405A (ja) 2008-05-15
JP2008515405A5 JP2008515405A5 (enExample) 2008-11-27
JP5101288B2 true JP5101288B2 (ja) 2012-12-19

Family

ID=36075582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007534921A Expired - Fee Related JP5101288B2 (ja) 2004-10-05 2005-10-05 アプタマー調節される核酸及びその利用
JP2012178625A Expired - Fee Related JP5795563B2 (ja) 2004-10-05 2012-08-10 アプタマー調節される核酸及びその利用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012178625A Expired - Fee Related JP5795563B2 (ja) 2004-10-05 2012-08-10 アプタマー調節される核酸及びその利用

Country Status (5)

Country Link
US (3) US9315862B2 (enExample)
EP (1) EP1799825B1 (enExample)
JP (2) JP5101288B2 (enExample)
AT (1) ATE514776T1 (enExample)
WO (1) WO2006042112A2 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
ATE514776T1 (de) * 2004-10-05 2011-07-15 California Inst Of Techn Aptamer-regulierte nukleinsäuren und verwendungen davon
US7727721B2 (en) 2005-03-08 2010-06-01 California Institute Of Technology Hybridization chain reaction amplification for in situ imaging
ATE526975T1 (de) 2005-10-07 2011-10-15 California Inst Of Techn Pkr-aktivierung mittels hybridisierungskettenreaktion
WO2007100412A2 (en) * 2005-12-21 2007-09-07 Yale University Methods and compositions related to the modulation of riboswitches
US20080026947A1 (en) * 2006-02-08 2008-01-31 Gmeiner William H Cytotoxic nucleotides for targeted therapeutics
US20090023221A1 (en) * 2006-05-19 2009-01-22 Exigon A/S Oligonucleotide probes useful for detection and analysis of microrna precursors
WO2007136833A2 (en) * 2006-05-19 2007-11-29 Codon Devices, Inc. Methods and compositions for aptamer production and uses thereof
WO2007147159A2 (en) * 2006-06-16 2007-12-21 Cornell Research Foundation, Inc. Functional nucleic acid ligands to fluorescent proteins
WO2008127382A2 (en) * 2006-10-19 2008-10-23 Yale University Computational design of ribozymes
WO2008058291A2 (en) 2006-11-09 2008-05-15 California Institute Of Technology Modular aptamer-regulated ribozymes
EP2471925A1 (en) * 2007-03-22 2012-07-04 Yale University Methods and compositions related to riboswitches that control alternative splicing
WO2008122088A1 (en) * 2007-04-05 2008-10-16 Lifeprint Australia Pty Ltd Methods for detecting a target nucleotide sequence in a sample utilising a nuclease-aptamer complex
JP5223237B2 (ja) * 2007-05-14 2013-06-26 ソニー株式会社 検出用核酸鎖及び物質間の結合又は相互作用検出方法
WO2008144562A1 (en) * 2007-05-16 2008-11-27 California Institute Of Technology A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
WO2009011855A2 (en) * 2007-07-16 2009-01-22 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
AU2008286701B2 (en) * 2007-08-14 2015-02-12 Commonwealth Scientific And Industrial Research Organisation Improved gene silencing methods
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8865667B2 (en) 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
US8329889B2 (en) * 2008-02-15 2012-12-11 Trustees Of Boston University In vivo gene sensors
US8497364B2 (en) * 2008-02-27 2013-07-30 California Institute Of Technology Triggered RNAi
JP5463621B2 (ja) * 2008-02-27 2014-04-09 ソニー株式会社 標的物質の定量方法
US20100021904A1 (en) * 2008-05-21 2010-01-28 Pierce Niles A Shielded cross-linking probes
US8241854B2 (en) * 2008-05-22 2012-08-14 California Institute Of Technology Triggered RNAi
US20100021901A1 (en) * 2008-05-22 2010-01-28 Peng Yin Compositions and methods for detecting analytes
WO2010005055A1 (ja) * 2008-07-09 2010-01-14 公立大学法人大阪市立大学 オリゴヌクレオチド構造体および遺伝子発現制御方法
CA2730083C (en) * 2008-07-11 2016-11-01 The Administrators Of The Tulane Educational Fund Stimulus-responsive apta-chelamers
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
US9145555B2 (en) * 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
US9284559B2 (en) * 2009-04-14 2016-03-15 Wake Forest University Health Sciences Multivalent aptamer complexes
WO2011050000A2 (en) * 2009-10-20 2011-04-28 The Regents Of The University Of California Single molecule nucleic acid nanoparticles
US8658780B2 (en) 2010-05-18 2014-02-25 California Institute Of Technology Triggered covalent probes for imaging and silencing genetic expression
WO2011163526A2 (en) * 2010-06-23 2011-12-29 California Institute Of Technology Signal activated molecular delivery
US9834439B2 (en) 2010-07-20 2017-12-05 California Institute Of Technology Biomolecular self-assembly
US8962241B2 (en) 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
US8877438B2 (en) 2010-07-20 2014-11-04 California Institute Of Technology Self-assembled polynucleotide structure
WO2012056441A1 (en) * 2010-10-28 2012-05-03 Nanodoc Ltd. Compositions and methods for specific cleavage of exogenous rna in a cell
US9115355B2 (en) 2011-06-23 2015-08-25 California Institute Of Technology Exonuclease resistant polynucleotide and related duplex polynucleotides, constructs, compositions, methods and systems
US9725715B2 (en) 2011-06-23 2017-08-08 California Institute Of Technology Signal activatable constructs and related components compositions methods and systems
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2013119888A1 (en) 2012-02-09 2013-08-15 President And Fellows Of Harvard College Selective nucleic acid amplification from nucleic acid pools
WO2013142735A1 (en) 2012-03-21 2013-09-26 California Institute Of Technology Targeting domain and related signal activated molecular delivery
JP5731016B2 (ja) * 2012-04-27 2015-06-10 キリン株式会社 リガンドを高感度に検出する核酸分子並びに該核酸分子のスクリーニング方法および該核酸分子の感度の最適化方法
US9856472B2 (en) 2013-07-01 2018-01-02 California Institute Of Technology Small conditional RNAs
CA2917627A1 (en) 2013-07-18 2015-01-22 President And Fellows Of Harvard College Specific nucleic acid amplification with compounded selectivity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9486533B2 (en) 2013-09-27 2016-11-08 Wake Forest University Health Sciences Pharmaceutical compositions for high-capacity targeted delivery
JP6267217B2 (ja) * 2013-09-30 2018-01-24 Ｎｅｃソリューションイノベータ株式会社 ターゲットの分析方法および分析キット
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
WO2015095633A1 (en) * 2013-12-20 2015-06-25 Board Of Regents, The University Of Texas System Methods and compositions related to nucleic acid circuits and signal transducers
EP3674408A1 (en) * 2014-06-16 2020-07-01 The Johns Hopkins University Compositions and methods for the expression of crispr guide rnas
WO2016018963A1 (en) 2014-07-30 2016-02-04 President And Fellows Of Harvard College Probe library construction
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
KR101719285B1 (ko) 2014-11-04 2017-03-23 한국과학기술원 표적 물질에 의해 조절되는 핵산 중합효소 활성을 이용한 생체물질의 검출 및 정량 방법
HUE054624T2 (hu) 2015-02-02 2021-09-28 Meiragtx Uk Ii Ltd A génexpresszió szabályozása az alternatív splicing aptamer által közvetített modulálásával
US9434996B1 (en) * 2015-03-13 2016-09-06 Tracy Ann Hayden All mini-STR multiplex with increased C.E. through-put by STR prolongation template fusion
US20180094309A1 (en) * 2015-04-03 2018-04-05 President And Fellows Of Harvard College Nucleic acid retro-activated primers
SG11201803173VA (en) 2015-10-23 2018-05-30 Harvard College Nucleobase editors and uses thereof
CA3029625A1 (en) 2016-07-05 2018-01-11 California Institute Of Technology Fractional initiator hybridization chain reaction
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US10815519B2 (en) 2016-08-30 2020-10-27 California Institute Of Technology Immunohistochemistry via hybridization chain reaction
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP4389894A3 (en) * 2017-03-10 2024-08-28 The Medical College of Wisconsin, Inc. Riboswitch modulated gene therapy for retinal diseases
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
KR20190140918A (ko) 2017-03-15 2019-12-20 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 검출을 위한 crispr 이펙터 시스템 기반 진단
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11788123B2 (en) 2017-05-26 2023-10-17 President And Fellows Of Harvard College Systems and methods for high-throughput image-based screening
WO2018226666A1 (en) * 2017-06-05 2018-12-13 Maumita Mandal Methods, compositions, and devices involving pseudoknot formation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
AU2018352592C1 (en) 2017-10-16 2025-09-25 Beam Therapeutics, Inc. Uses of adenosine base editors
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
AU2019398322A1 (en) 2018-12-13 2021-06-24 President And Fellows Of Harvard College Amplification methods and systems for MERFISH and other applications
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB2601617B (en) 2019-03-19 2024-02-21 Broad Inst Inc Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
JP2023517054A (ja) * 2020-03-06 2023-04-21 カリフォルニア インスティチュート オブ テクノロジー ハイブリダイゼーション連鎖反応を介した試料内の標的分子の分析
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
CN116096729A (zh) * 2020-05-27 2023-05-09 威廉马歇莱思大学 Dna扩增反应中的不可延伸的寡核苷酸
WO2022164796A1 (en) 2021-01-26 2022-08-04 California Institute Of Technology Allosteric conditional guide rnas for cell-selective regulation of crispr/cas
KR102661292B1 (ko) * 2021-09-09 2024-04-30 포항공과대학교 산학협력단 금속 이온 반응성 dna 중합 효소 스위치 및 이에 의해 제어되는 등온 증폭 방법
US20250302992A1 (en) * 2021-12-15 2025-10-02 Meiragtx Uk Ii Limited Polycistronic Expression of Gut Peptides

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019A (en) * 1849-01-09 Cast-iron car-wheel
US1000289A (en) 1910-09-14 1911-08-08 Arthur Low Patterson Stocking-folder.
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
EP0260032B1 (en) * 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
ZA902710B (en) 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DE69133511T2 (de) 1990-08-13 2006-09-28 Isis Pharmaceuticals, Inc., Carlsbad Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
US5500357A (en) * 1990-11-02 1996-03-19 Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry RNA transcription system using novel ribozyme
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5525719A (en) * 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
US5214135A (en) * 1991-08-30 1993-05-25 Chemgenes Corporation N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5756291A (en) * 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US5583020A (en) * 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) * 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US5534259A (en) * 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5777153A (en) * 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) * 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5736392A (en) * 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5851548A (en) * 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
AU2994997A (en) 1996-05-07 1997-11-26 T Cell Sciences, Inc. Aptamers for complement protein c3b
WO1999004800A1 (en) 1997-07-22 1999-02-04 Genitrix, Llc Nucleic acid compositions and methods of introducing nucleic acids into cells
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
WO1999027133A1 (en) 1997-11-26 1999-06-03 Medical Research Council Improved selex procedure and an anti-cd4 aptamer
US6180348B1 (en) 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
US6458559B1 (en) * 1998-04-22 2002-10-01 Cornell Research Foundation, Inc. Multivalent RNA aptamers and their expression in multicellular organisms
WO1999055857A2 (en) * 1998-04-29 1999-11-04 Ribozyme Pharmaceuticals, Inc. Nucleoside triphosphates and their incorporation into ribozymes
US7001733B1 (en) * 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
WO2000011218A1 (en) * 1998-08-21 2000-03-02 Affymetrix, Inc. Expression monitoring for human cytomegalovirus (hcmv) infection
WO2000020040A1 (en) 1998-10-08 2000-04-13 University Of Massachusetts Controlling gene expression in living cells
US20060172925A1 (en) * 1998-10-26 2006-08-03 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US20060121510A1 (en) * 1998-11-03 2006-06-08 Breaker Ronald R Multidomain polynucleotide molecular sensors
US6958215B1 (en) * 1999-03-15 2005-10-25 Geron Corporation Methods and compositions for inhibition of RNA splicing
US6951722B2 (en) * 1999-03-19 2005-10-04 Takara Bio Inc. Method for amplifying nucleic acid sequence
US20040072785A1 (en) * 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US7098030B2 (en) * 1999-12-31 2006-08-29 Mirus Bio Corporation Polyampholytes for delivering polyions to a cell
AU2001245793A1 (en) * 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
AU2001259586A1 (en) * 2000-05-05 2001-11-20 Agilix Corporation Highly multiplexed reporter carrier systems
US20030104520A1 (en) * 2000-06-15 2003-06-05 Ellington Andrew D. Regulatable, catalytically active nucleic acids
US6706474B1 (en) * 2000-06-27 2004-03-16 Board Of Trustees Of The University Of Illinois Nucleic acid enzyme biosensors for ions
IL154508A0 (en) * 2000-08-18 2003-09-17 Gencell Sa System for regulating in vivo the expression of a transgene by conditional inhibition
US7115369B2 (en) * 2001-03-15 2006-10-03 Iowa State University Research Foundation, Inc. Functional nucleic acid probes and uses thereof
US6951720B2 (en) * 2001-05-10 2005-10-04 San Diego State University Foundation Use of phosphorothiolate polynucleotides in ligating nucleic acids
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20030157030A1 (en) * 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
EP1451588A4 (en) * 2001-11-06 2005-03-09 Agilix Corp SENSITIVE CODED DEFINITION SYSTEMS
AU2002343792A1 (en) * 2001-11-28 2003-06-10 Center For Advanced Science And Technology Incubation, Ltd. siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
WO2004033653A2 (en) * 2002-10-10 2004-04-22 Oxford Biomedica (Uk) Limited Gene regulation with aptamer and modulator complexes for gene therapy
EP1585756B1 (en) * 2002-11-26 2010-04-21 University of Massachusetts Delivery of sirnas
DE10302421A1 (de) 2003-01-21 2004-07-29 Ribopharma Ag Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
US20040162235A1 (en) * 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
US20050026286A1 (en) * 2003-03-05 2005-02-03 Jen-Tsan Chi Methods and compositions for selective RNAi mediated inhibition of gene expression in mammal cells
WO2005001039A2 (en) * 2003-05-29 2005-01-06 Creighton University Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
US20060178327A1 (en) * 2003-05-30 2006-08-10 Yeung Wah Hin A Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7672786B2 (en) * 2003-07-02 2010-03-02 Sergey Krylov Non-equilibrium capillary electrophoresis of equilibrium mixtures (NECEEM)—based methods for drug and diagnostic development
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4951338B2 (ja) * 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド 脂質に封入された干渉ｒｎａ
US20050265957A1 (en) * 2004-04-08 2005-12-01 Monahan Sean D Polymerized formamides for use in delivery of compounds to cells
US20060105975A1 (en) * 2004-04-19 2006-05-18 Shannon Pendergrast Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
AU2005252273B2 (en) * 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
ATE514776T1 (de) 2004-10-05 2011-07-15 California Inst Of Techn Aptamer-regulierte nukleinsäuren und verwendungen davon
WO2006086669A2 (en) 2005-02-09 2006-08-17 California Institute Of Technology Aptamer regulated nucleic acids and uses thereof
US20060200878A1 (en) * 2004-12-21 2006-09-07 Linda Lutfiyya Recombinant DNA constructs and methods for controlling gene expression
JP2009523823A (ja) * 2006-01-23 2009-06-25 アボット・ラボラトリーズ ｓｉＲＮＡ送達のための化学的に修飾されたポリカチオンポリマー
EP1986609A2 (en) 2006-01-26 2008-11-05 University of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
ES2610703T3 (es) * 2006-06-23 2017-05-03 Engeneic Molecular Delivery Pty Ltd. Administración dirigida de fármacos, ácidos nucleicos terapéuticos y ácidos nucleicos funcionales a células mamíferas mediante células bacterianas muertas intactas
KR101133799B1 (ko) * 2006-08-18 2012-04-24 에프. 호프만-라 로슈 아게 폴리뉴클레오타이드의 생체내 전달을 위한 다가접합체
US8252755B2 (en) 2006-09-22 2012-08-28 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
WO2008058291A2 (en) 2006-11-09 2008-05-15 California Institute Of Technology Modular aptamer-regulated ribozymes
WO2009011855A2 (en) * 2007-07-16 2009-01-22 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US8865667B2 (en) * 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
US8329882B2 (en) * 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
US9145555B2 (en) * 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs

Also Published As

Publication number Publication date
ATE514776T1 (de) 2011-07-15
JP2008515405A (ja) 2008-05-15
JP5795563B2 (ja) 2015-10-14
JP2012223201A (ja) 2012-11-15
US20060088864A1 (en) 2006-04-27
WO2006042112A9 (en) 2006-06-29
US8772464B2 (en) 2014-07-08
EP1799825B1 (en) 2011-06-29
EP1799825A2 (en) 2007-06-27
WO2006042112A2 (en) 2006-04-20
US20120035065A1 (en) 2012-02-09
US9309568B2 (en) 2016-04-12
US9315862B2 (en) 2016-04-19
US20150024954A1 (en) 2015-01-22
WO2006042112A3 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
JP5101288B2 (ja) アプタマー調節される核酸及びその利用
US9040495B2 (en) General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) Modular polynucleotides for ligand-controlled regulatory systems
US8603996B2 (en) Modular aptamer-regulated ribozymes
Taylor et al. A modular XNAzyme cleaves long, structured RNAs under physiological conditions and enables allele-specific gene silencing
US20090082217A1 (en) Selection of nucleic acid-based sensor domains within nucleic acid switch platform
US8865667B2 (en) Higher-order cellular information processing devices
WO2020033938A1 (en) Programmable conditional sirnas and uses thereof
Scherr et al. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA
US20100292299A1 (en) Nucleotide Motifs Providing Localization Elements and Methods of Use
Bansal MicroRNA therapeutics: Discovering novel targets and developing specific therapy
Shestopalov et al. Oligonucleotide-based tools for studying zebrafish development
CN101072874A (zh) 适体调节的核酸及其应用
US8604176B2 (en) Protein-responsive RNA control devices and uses thereof
Pérez et al. MicroRNA interference
Zhu et al. MiRNA Locker: A Modularized DNA Assembly As miRNA Inhibitors
EP3746555B1 (en) Inhibition of a lncrna for treatment of neuroblastoma
Singh et al. Modulating populational variance of methyl-guanine methyl transferase expression through miR-181d degradation: a novel mechanism of temozolomide resistance
US20120110686A1 (en) Cand45 tRNA-Derived Expression System for Gene Modulation
Yi et al. Efficient Silencing of Gene Expression by an ASON–Bulge–DNAzyme Complex
Jain et al. Technologies, Companies & Markets
Crater et al. Antisense technologies in the studying of Toxoplasma gondii
Rossi RNA interference: application to drug discovery and challenges to pharmaceutical development
Lataniotis et al. Gene Editing and Specific MicroRNA Inhibition
Litke A Ribozyme-Mediated Mammalian Expression System and Its Utility for RNA-Based Devices and Aptamers in Live Cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111005

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120710

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120904

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120926

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151005

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5101288

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees